Breast Cancer Clinical Trial
— PECSOfficial title:
The Analgesic Efficacy of the Pectoral Nerves Block Versus Local Anesthetic Infiltration After Mastectomy: a Randomized, Controlled, Double Blinded Trial
This trial will include patients undergoing radical mastectomy under general anesthesia. One group of patients will receive a pectoral nerve block, done by the anesthetist under ultrasound guidance at the beginning of the invervention. The other group will receive the a wound infiltration at the end of the intervention, done by the surgeon. Investigators will compare acute pain-related outcomes and chronic pain at 3 and 6 months postoperatively.
| Status | Not yet recruiting |
| Enrollment | 50 |
| Est. completion date | June 30, 2021 |
| Est. primary completion date | December 31, 2020 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Patients undergoing unilateral mastectomy - American Society of Anesthesiology Physical Status I-III - Age = 18 Exclusion Criteria: - Contraindications to regional anesthesia, such as infection at the surgical site - Pregnancy - History of alcohol or drug dependence/abuse - History of long term opioid intake - Chronic pain disorder |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Hôpital du Valais | University of Lausanne Hospitals |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Morphine consumption | Cumulative intravenous morphine consumption (mg) | first 24 postoperative hours | |
| Secondary | Pain score at rest at 2 hours postoperatively | Numeric rating scale from 0 = no pain to 10 = worst imaginable pain | 2 hours postoperatively | |
| Secondary | Pain score at rest at 12 hours postoperatively | Numeric rating scale from 0 = no pain to 10 = worst imaginable pain | 12 hours postoperatively | |
| Secondary | Pain score at rest at 24 hours postoperatively | Numeric rating scale from 0 = no pain to 10 = worst imaginable pain | 24 hours postoperatively | |
| Secondary | Pain score on movement at 2 hours postoperatively | Numeric rating scale from 0 = no pain to 10 = worst imaginable pain | 2 hours postoperatively | |
| Secondary | Pain score on movement at 12 hours postoperatively | Numeric rating scale from 0 = no pain to 10 = worst imaginable pain | 12 hours postoperatively | |
| Secondary | Pain score on movement at 24 hours postoperatively | Numeric rating scale from 0 = no pain to 10 = worst imaginable pain | 24 hours postoperatively | |
| Secondary | Time to first analgesic request | Time between end of surgery and first analgesic request by patient, in minutes | 24 hours postoperatively |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |